Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia
Open Access
- 9 September 2004
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 18 (11), 1907-1909
- https://doi.org/10.1038/sj.leu.2403502
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trialBone Marrow Transplantation, 2004
- Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2003
- Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisisBone Marrow Transplantation, 2003
- Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia, 2002
- Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaBlood, 2002
- Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemiaBritish Journal of Haematology, 2000
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996